Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Trade With Artificial Intelligence For Happiness (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Trade With Artificial Intelligence For Happiness (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
Trade With Artificial Intelligence For Happiness (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Trade With Artificial Intelligence For Happiness (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Trade With Artificial Intelligence For Happiness (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
Trade With Artificial Intelligence For Happiness (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Trade With Artificial Intelligence For Happiness (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Trade With Artificial Intelligence For Happiness (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
Trade With Artificial Intelligence For Happiness (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Trade With Artificial Intelligence For Happiness (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Trade With Artificial Intelligence For Happiness (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
Trade With Artificial Intelligence For Happiness (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$38.98
-1.36 (-3.37%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$37.93
$40.75
50-Day Range
$38.79
$57.24
52-Week Range
$34.90
$83.40
Volume
597,239 shs
Average Volume
450,632 shs
Market Capitalization
$2.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.19

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
101.9% Upside
$78.69 Price Target
Short Interest
Bearish
11.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.43mentions of Arvinas in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.81) to ($5.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

757th out of 1,040 stocks

Pharmaceutical Preparations Industry

366th out of 509 stocks

ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

FY2024 EPS Estimates for Arvinas, Inc. (NASDAQ:ARVN) Cut by Analyst
Arvinas (NASDAQ:ARVN) Price Target Raised to $81.00
Arvinas (NASDAQ:ARVN) PT Lowered to $70.00
Arvinas (NASDAQ:ARVN) Price Target Cut to $74.00
Arvinas to Present at Upcoming Conferences
Why Arvinas (ARVN) Might Surprise This Earnings Season
Arvinas Gives Back to Local Greater New Haven Community
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
11/08/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.69
High Stock Price Forecast
$102.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+103.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

Net Income
$-191,000,000.00
Net Margins
-225.34%
Pretax Margin
-216.24%

Debt

Sales & Book Value

Annual Sales
$46.70 million
Book Value
$14.78 per share

Miscellaneous

Free Float
51,748,000
Market Cap
$2.07 billion
Optionable
Not Optionable
Beta
1.89

Key Executives

  • Dr. John G. Houston Ph.D. (Age 62)
    CEO, Pres & Director
    Comp: $1.07M
  • Mr. Sean A. Cassidy CPAMr. Sean A. Cassidy CPA (Age 52)
    CPA, M.B.A., CFO & Treasurer
    Comp: $667.73k
  • Dr. Ian Taylor Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $686.8k
  • Dr. Ronald A. PeckDr. Ronald A. Peck
    Chief Medical Officer
  • Mr. Jeff Boyle
    VP of Investor Relations
  • Mr. Matthew Batters J.D. (Age 47)
    Gen. Counsel & Corp. Sec.
  • Dr. Randy Teel Ph.D. (Age 43)
    Sr. VP of Corp. & Bus. Devel.
  • Mr. Steve Weiss (Age 52)
    Sr. VP & Chief HR Officer
  • Dr. John A. Grosso Ph.D. (Age 65)
    Sr. VP of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 54)
    Sr. VP of Neuroscience & Platform Biology













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

17 brokerages have issued 1 year price objectives for Arvinas' stock. Their ARVN share price forecasts range from $42.00 to $102.00. On average, they expect the company's share price to reach $78.69 in the next twelve months. This suggests a possible upside of 101.9% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2022?

Arvinas' stock was trading at $82.14 at the start of the year. Since then, ARVN stock has decreased by 52.5% and is now trading at $38.98.
View the best growth stocks for 2022 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 8th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.26. The firm earned $30.30 million during the quarter, compared to analyst estimates of $44.20 million. Arvinas had a negative trailing twelve-month return on equity of 36.12% and a negative net margin of 225.34%.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.85%), BlackRock Inc. (6.96%), Bellevue Group AG (4.12%), Price T Rowe Associates Inc. MD (4.10%), State Street Corp (2.04%) and Pictet Asset Management SA (0.94%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $38.98.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $2.07 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.76) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 11/29/2022 by MarketBeat.com Staff